FINANCIAL CONFLICT OF INTEREST POLICY

Similar documents
1. Disclosure of Significant Financial Interest means an Investigator s disclosure of significant financial interests to Monmouth University.

Last Review Date: 07/14/2015 Last Revised Date: 07/14/2015 Next Review Due: 07/14/2018 Policy Owner:

Investigator Conflicts of Interest in Funded Research

INTERNATION CENTER FOR RESEARCH ON WOMEN (ICRW) PHS FUNDED RESEARCH FINANCIAL CONFLICT OF INTEREST (FCOI) POLICY

Auburn University Procedures for Public Health Service Financial Conflicts of Interest Regulations

University of New England Investigator Significant Financial Interest Disclosure Policy for Sponsored Projects Originally Adopted March 2005

Florida Agricultural and Mechanical University Board of Trustees Policy

PROCEDURE. Overview. Purpose. in order to comply with PHS regulations (US regulations: 42 CFR Part 50 Subpart F and 45 CFR Part 94).

RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (RFMH) FINANCIAL CONFLICT OF INTEREST POLICY

REGENERON PHARMACEUTICALS, INC. FINANCIAL CONFLICTS OF INTEREST POLICY FOR PHS-FUNDED RESEARCH

Investigator Financial Conflict of Interest Policy

Objectivity in Research and Investigator Financial Disclosure

Financial Conflicts of Interest (FCOI) in Federally Sponsored Research John Dowd, Vice President of Human Resources

VNSNY CORPORATE POLICY AND PROCEDURE

Kentucky State University Financial Conflict of Interest in Federally Funded Research Policy

Moffitt Cancer Center

UNIVERSITY OF WISCONSIN-STEVENS POINT OFFICE OF RESEARCH AND SPONSORED PROGRAMS

Clemson University Financial Conflict of Interest Policy for PHS/NIH Supported Research

Title: Previous Version(s): 8/01, 1/02, 6/06, 1/12, 4/12

Financial Conflict of Interest (FCOI) Standard Operating Procedures

Marquette University Promoting Objectivity in Research/Financial Conflict of Interest for Public Health Services Investigators

Committee Approval(s) Standards Committee 06/19/13. Current Content Expert: Megan Bailey, Manager, Office of Research Compliance

Dakota State University Policy Manual

FINANCIAL CONFLICT OF INTEREST PLAN. November, 2013

Financial Conflict of Interest Policy

AMERICAN CANCER SOCIETY, INC. FINANCIAL CONFLICT OF INTEREST POLICY FOR PROMOTING OBJECTIVITY IN RESEARCH

2.1 To clarify requirements regarding reporting of Significant Financial Interests (SFIs) by persons at CCMB.

Partners In Health Financial Conflicts of Interest Policy

TITLE: Conflict of Interest, Research

Financial Conflict of Interest Policy for Federally-funded Research

Financial Conflict of Interest for Externally Funded Research Reporting Process (July 1, 2017)

John Kearny, Janice Nicholson, Patricia Notarangelo, Rebbie Pamintuan, Nadia Taylor. Additional Editors: Gwen Burrows Additional Readers:

MANUAL OF UNIVERSITY POLICIES PROCEDURES AND GUIDELINES. Applies to: faculty staff students student employees visitors contractors

MODEL POLICY [INSERT NAME OF YOUR ORGANIZATION] CONFLICT OF INTEREST POLICY APPLICABLE TO A SUBAWARD ISSUED UNDER A PUBLIC HEALTH SERVICES PRIME AWARD

TEMPLE UNIVERSITY BOARD OF TRUSTEES POLICIES AND PROCEDURES MANUAL

Policy on Conflicts of Interest in Public Health Service Sponsored Programs

Johnson & Johnson Financial Conflicts of Interest Policy

Policy Number: Location: Origination Date: Date of Last Review: Baylor Research Institute 8/24/2012 7/11/2012

Financial Conflict of Interest Policy and Procedural Manual

This Financial Conflict of Interest Policy is designed to maintain the trust of the public, research volunteers and the University research community.

2018 SRAI Annual Meeting October 27-31

complying with the State Conflict of Interests Act are described below.

OBJECTIVITY IN RESEARCH POLICY

UNI Office of Research and Sponsored Programs Policy on Conflicts of Interest Involving Research Funded by the Public Health Service

Financial Conflict of Interest (FCOI) Training for Investigators

II. POLICY STATEMENT RELATING TO CONFLICTS OF INTEREST

POLICY NO.: BHSF POLICY TITLE: Individual Financial Conflicts of Interest (FCOI) in Research

(** Note: This Policy shall replace the current Section IV. Chapter 2 Policy in its entirety**). Section IV. Research and Sponsored Projects

Central Office of Research Administration

Research Financial Conflict of Interest Policy. I. Policy Statement

Financial Conflict of Interest Guidelines Office of Research & Commercialization August 24, 2012

The following definitions will be used to inform the policy implementation:

Policy of Financial Interests Related to U.S. Public Health Service (USPHS) Sponsored Projects for Promoting Objectivity in Research

What is a Conflict of Interest (COI) or Financial Conflict of Interest (FCOI)?

Financial Conflict of Interest. V001 November 14, 2014

GUIDANCE: Financial Conflicts of Interest NUMBER DATE AUTHOR APPROVED BY AUDIENCE USE PAGE

Becton, Dickinson and Company Policy on Conflicts of Interest Related to Research

Office of Research Administration

Conflicts of Interest - Research and Sponsored Programs

Financial Disclosure Form for Investigators in PHS Research

The Rockefeller University Policy on Financial Conflict of Interest in Research

Standard Operating Procedures for Disclosure and Management of Financial Conflicts of Interest

SILENT SPRING INSTITUTE POLICY AND PROCEDURES ON FINANCIAL CONFLICTS OF INTEREST IN PUBLIC HEALTH SERVICE FUNDED RESEARCH

This policy has been adapted from the Conflict of Interest in Research Policy at Tufts University.

Division of Research Policy

CREARE POLICY ON FINANCIAL CONFLICTS OF INTEREST IN PUBLIC HEALTH SERVICE-FUNDED RESEARCH

CONFLICT OF INTEREST RULES AND PROCEDURES

Biomedical Research Institute of New Mexico. Financial Conflict of Interest Objectivity in Research

XAVIER UNIVERSITY. Financial Conflict of Interest Policy-Non-Federal Grant Proposals

NEW FINANCIAL CONFLICT OF INTEREST (FCOI) REGULATORY REQUIREMENTS

The Rockefeller University Policy on Financial Conflict of Interest and Conflict of Commitment in Research. Financial Conflict of Interest

Conflict of commitment, nepotism, and institutional COI are addressed in other policies and procedures.

MAIMONIDES MEDICAL CENTER SUBJECT: CONFLICTS OF INTEREST IN HUMAN RESEARCH & PHS FUNDED RESEARCH

RESEARCH INVESTIGATOR CONFLICT OF INTEREST

To: Vice Chancellors, Deans, Administrative Staff, Department Heads, and Students.

These Compliance Guidelines apply to all Covered Researchers and Subrecipients planning to participate in or who are engaged in PHS-Funded Research.

Office of Research Administration

Disclosure of Financial Interests & Management of Conflicts of Interest, Public Health Service Research Awards

Conflict of Interest Policy. Approved May 2016 Mayo Clinic Board of Governors

Kaiser Permanente policy on conflicts of interest in research

DRAFT University of South Florida System Policy

Frequently Asked Questions on the PHS COI Regulations

DIGNITY HEALTH ADMINISTRATIVE POLICY AND PROCEDURE. Conflicts of Interest Institutional Review Boards, Facilities, and Investigators

Conflict of Interest Policy. Approved August 2012 Mayo Clinic Board of Governors

POLICY ON DISCLOSURE OF SIGNIFICANT FINANCIAL INTEREST

CAROLINAS HEALTHCARE SYSTEM OFFICE OF CLINICAL AND TRANSLATIONAL RESEARCH STANDARD OPERATING PROCEDURE

MASSACHUSETTS INSTITUTE OF TECHNOLOGY POLICY AND PROCEDURES ON CONFLICTS OF INTEREST IN RESEARCH

Conflicts of Interest and Commitment Policy

Administrative Procedure, AP Procedures for Disclosing and Addressing Conflicts of Interest and Commitment. Page 1 of 14

Financial Conflict of Interest

Florida Hospital Office of Research Integrity 901 N Lake Destiny Drive, Suite 400 Maitland, FL , ext

CONFLICTS OF INTEREST IN RESEARCH - INDIVIDUAL

Disclosure of Financial Interests and Management of Conflicts of Interest Related to Sponsored Projects (Research)

LSUHSC-NO Chancellor s Memorandum (CM-35)

Investigators, which includes any individual responsible for the design, conduct, or reporting of the research.

ALBERT EINSTEIN COLLEGE OF MEDICINE COMPREHENSIVE CONFLICT OF INTEREST POLICY

NOTES ON CONFLICT OF INTEREST

Research Compliance Overview for CRA Certification

Welcome to UMB s PHS Training Module for PHS- Funded Investigators

Effective Date August 1, Date of Last Review September 2016 Date of Next Review September Date of Adoption October 2003.

Transcription:

FINANCIAL CONFLICT OF INTEREST POLICY Noble Research Institute (the Institute ) seeks to ensure the integrity and excellence of its research, and it is the responsibility of all individuals engaged in research at the Institute to discharge their duties accordingly and preserve public trust in the integrity of the Institute. The purpose of this Financial Conflict of Interest Policy (this Policy ) is to establish procedures that will provide a reasonable expectation that the design, conduct, and reporting of research will be free from bias resulting from financial conflicts of interest. Purpose This Policy is intended to conform to the federal Public Health Service s regulations regarding financial conflicts of interest (Title 42 Code of Federal Regulations, Part 50, Subpart F, Responsibility of Applicants for Promoting Objectivity in Research for Which PHS Funding is Sought) (the FCOI Regulations ) and the National Science Foundation s policy (the NSF Policy ) regarding financial conflicts of interest. Although this Policy is based on the FCOI Regulations and the NSF Policy, this Policy applies to all projects funded by federal agencies (each an Agency ), except as otherwise noted below. Should this Policy conflict with the rules of any Agency pertaining to financial conflicts of interest, the Agency rules shall apply. Definitions Agency Awarding Component means the organizational unit of an Agency that funds the Research. Financial Conflict of Interest ( FCOI ) means a Significant Financial Interest that could directly and significantly affect the design, conduct, or reporting of Research. Institutional Responsibilities means an Investigator s professional responsibilities on behalf of the Institute, which may include for example: activities such as Research, research consultation, mentoring, professional practice, institutional committee memberships, and service on panels such as Institutional Review Boards or Data and Safety Monitoring Boards. Investigator means the principal investigator ( PI ), co-principal investigators, or any other person, regardless of title or position, who is responsible for the design, conduct, or reporting of Research funded by an Agency, or proposal for such funding, which may include, for example, collaborators or consultants. Manage means taking action to address an FCOI, which can include reducing or eliminating the financial conflict of interest to ensure, to the extent possible, that the design, conduct and reporting of Research will be free from bias. Management Plan means a written plan specifying actions that have been and shall be taken to Manage an identified FCOI. NSF means the National Science Foundation. PHS means the Public Health Service of the U.S. Department of Health and Human Services, and any component of the PHS to which the authority involved may be delegated, including the National Institutes of Health ( NIH ). Responsible Department: Legal Affairs Page 1 of 9

Research means a systematic investigation, study or experiment designed to develop or contribute to generalizable knowledge relating broadly to public concern or benefit. The term encompasses basic and applied research (e.g., a published article, book or book chapter) and product development. The term includes any such activity for which research funding is available from an Agency Awarding Component through a grant or cooperative agreement. Senior/Key Personnel means the PI and any other person identified as senior/key personnel by the Institute in the grant application, progress report, or any other report submitted to the funding Agency by the Institute. Significant Financial Interest for NSF-funded projects means anything of monetary value, including, but not limited to, salary or other payments for services (e.g., consulting fees or honoraria); equity interest (e.g., stocks, stock options, or other ownership interests); and intellectual property rights (e.g., patents, copyrights, and royalties from such rights). The following do not constitute Significant Financial Interests: Salary, royalties, or other remuneration from the Institute; Income from seminars, lectures, or teaching engagements sponsored by public or nonprofit entities; Income from service on advisory committees or review panels for public or nonprofit entities; An equity interest that, when aggregated for the Investigator and the Investigator s spouse and dependent children, meets both of the following tests: does not exceed $10,000 in value as determined through reference to public prices or other reasonable measures of fair market value, and does not represent more than a 5% ownership interest in any single entity; or Salary, royalties, or other payments that, when aggregated for the Investigator and the Investigator s spouse and dependent children, are not expected to exceed $10,000 during the prior twelve month period. Significant Financial Interest for all other projects by an Agency, including PHS-funded projects, means A financial interest consisting of one or more of the following interests of the Investigator (and those of the Investigator s spouse and dependent children) that reasonably appears to be related to the Investigator s institutional responsibilities: - With regard to any publicly traded entity, a significant financial interest exists when the value of any remuneration (salary and any payment for services not otherwise identified as salary, for example consulting fees, honoraria, paid authorship) received from the entity in the twelve (12) months preceding disclosure of the interest aggregated with the value of any equity in the entity (for example, stock, stock options, or other ownership interests as determined through reference to public prices or other reasonable measure of fair market value) in the entity as of the date of the disclosure, when aggregated, exceeds $5,000. - With respect to any non-publicly traded entity, when the aggregated value of any remuneration received from the entity in the twelve (12) months preceding disclosure of the interest, when aggregated, exceeds $5,000, or when the Investigator (or the Investigator s spouse or dependent children) holds any equity interest (e.g., stock, stock option, or other ownership interest) in the entity; or Responsible Department: Legal Affairs Page 2 of 9

- Intellectual property rights and interests (e.g., patents, copyrights) upon receipt of income related to such rights and interests. Investigators must also disclose the occurrence of any reimbursed or sponsored travel (i.e., that which is paid on behalf of the Investigator and not reimbursed to the Investigator so that the exact monetary value may not be readily available), related to their institutional responsibilities, however, this disclosure requirement does not apply to travel that is reimbursed or sponsored by a federal, state, or local government agency, an institution of higher education as defined in 20 USC 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an institution of high learning. This disclosure must include the purpose of the trip, the identity of the sponsor/organizer, the destination, and the duration. The term Significant Financial Interest does not include the following types of financial interests: salaries, royalties, or other remuneration paid by the Institute to the Investigator if the Investigator is currently employed or otherwise appointed by the Institute, including intellectual property rights assigned to the Institute and agreements to share in royalties related to such rights; income from investment vehicles, such as mutual funds and retirement accounts, as long as the Investigator does not directly control the investment decisions made in these vehicles; income from seminars, lectures or teaching engagements sponsored by, and service on advisory committees or review panels for, a federal, state or local government agency, an institution of higher education as defined in 20 U.S.C. 1001(a), an academic teaching hospital, a medical center or a research institute that is affiliated with an institution of higher education. Signing Official is the person responsible for the procedures under this Policy. The chief financial officer has been designated as the Signing Official (or authorized organizational representative ) for the Institute. Principles and Procedures Mandatory Investigator Training Requirements The Signing Official is responsible for ensuring that each Investigator is informed about (i) this FCOI Policy, (ii) the Investigator s responsibilities regarding disclosure of Significant Financial Interests relating to the Investigator s Institutional Responsibilities and (iii) the FCOI Regulations, the NSF Policy, and any other applicable Agency rules. The Signing Official shall ensure that each Investigator completes training regarding items (i) (iii) prior to engaging in Research related to any Agency-funded grant or cooperative agreement, immediately upon being hired and at least every four (4) years. The Signing Official also shall ensure that each Investigator completes training immediately when any of the following applies, as advised by the general counsel: (1) this FCOI Policy or procedures are revised in any manner that affects the requirements of the Investigators; (2) the Investigator is new to the Institute; or (3) the Institute finds that an Investigator is not in compliance with this FCOI Policy or a Management Plan. Immediately means the training is provided or made accessible and the Investigators participate in the training expeditiously following the event that triggers the training requirement. The Signing Official, in consultation with the general counsel, shall create and administer the training session. Responsible Department: Legal Affairs Page 3 of 9

Disclosure Requirements Officers, members of the leadership team and principal investigators annually shall complete and submit to the president a Disclosure of Outside Interests and Commitments form. Prior to the submission to an Agency of an application for a Research grant, the principal investigator shall identify to the Signing Official (1) all Investigators anticipated to be participating in the Research, (2) those who are Senior/Key personnel and (3) all subrecipients anticipated to be participating in the Research. Prior to submission of the application, each Investigator who is planning to participate in the Agencyfunded Research must (a) update their Disclosure of Outside Interests and Commitments form, if necessary or (b) complete a disclosure form listing his/her known Significant Financial Interests (and those of the Investigator s spouse and dependent children). The Institute s general counsel and/or the Signing Official will provide the Disclosure forms. All disclosures must be updated annually during the period of the award and within thirty (30) days of discovering or acquiring (e.g., through purchase, marriage, inheritance or expansion of responsibilities) a new Significant Financial Interest. Updates shall include any information that was not disclosed previously to the Institute and updated information regarding any previously disclosed Significant Financial Interest. The Signing Official, working with the Institute s secretary, shall ensure that annual update forms are sent to and promptly returned by at least each Investigator. One annual disclosure is sufficient to cover all ongoing federal awards. Disclosures shall be provided by an Investigator at any other time upon request of the Signing Official. The Signing Official shall ensure that each Investigator new to the Institute submits a listing of his/her known Significant Financial Interests (and those of his/her spouse and dependent children), if any, within thirty (30) days of starting employment. Review of Disclosures and Monitoring and Reporting FCOI The Signing Official with the general counsel shall be responsible for reviewing all forms disclosing a Significant Financial Interest, making the requisite determinations and taking any subsequent action. Prior to the expenditure of funds or, with respect to an ongoing Agency-funded project, within sixty (60) days of the disclosure or discovery of a Significant Financial Interest, the Signing Official shall: Review all disclosure forms and determine whether (a) an Investigator s Significant Financial Interest is related to Agency-funded Research and (b) if so related, whether the Significant Financial Interest is a FCOI; In the case of a FCOI, develop and implement a Management Plan; and If required by applicable Agency rules (see FCOI Report section below), submit initial and ongoing FCOI reports to the corresponding Agency Awarding Component. An Investigator s Significant Financial Interest is related to Agency-funded Research when the Signing Official reasonably determines that the Significant Financial Interest could be affected by the Agencyfunded Research or is in an entity whose financial interest could be affected by the Research. In determining whether an Investigator s Significant Financial Interest is related to Agency-funded Research, the Signing Official will consider all relevant factors and information. Responsible Department: Legal Affairs Page 4 of 9

A FCOI exists when the Signing Official reasonably determines that the Significant Financial Interest could directly and significantly affect the design, conduct, or reporting of the Agency-funded Research. In determining whether there is an FCOI, the Signing Official will consider all relevant factors and information, including but not limited to the nature of the Research, the magnitude of the financial interest and degree to which it is related to the Research, the extent to which the interest could be directly and substantially impacted by the Research, and the degree of risk to human subjects, if any, that is inherent in the Research protocol. Prior to making the decision whether an FCOI exists, the Signing Official may impose interim measures, may ask the Investigator to submit additional information and may meet or communicate with the Investigator. The Investigator may be encouraged to suggest procedures, protocols, or other measures designed to Manage the FCOI. If an FCOI exists, the Signing Official must develop and implement a Management Plan to Manage the FCOI. Examples of conditions or restrictions that might be imposed to Manage an FCOI include, but are not limited to: Public disclosure of FCOI (e.g., when presenting or publishing the Research); For Research involving human subjects, disclosure of financial conflicts to Research participants; Appointment of an independent monitor capable of taking measures to protect the design, conduct, and reporting of the Research against bias resulting from the FCOI; Modification of the Research plan; Change of personnel or personnel responsibilities or disqualification from participation in all or a portion of the Research; Reduction or elimination of the financial interest; and/or Severance of relationships that create such conflicts. For all Management Plans, the Signing Official shall (1) monitor ongoing Investigator compliance and (2) if required by the applicable Agency rules, submit annual FCOI reports to the corresponding Agency Awarding Component at the time and in the manner specified by the corresponding Agency Awarding Component, both until the completion of the Agency-funded research project to which the FCOI relates. For NSF-funded Research, if the Signing Official determines that imposing conditions or restrictions would be either ineffective or inequitable, and that the potential negative impacts that may arise from a Significant Financial Interest are outweighed by interests of scientific progress, technology transfer, or the public health and welfare, then the Signing Official may allow the research to go forward without imposing such conditions or restrictions. The Signing Official must inform the Agency if the Institute finds that it is unable to satisfactorily Manage a conflict of interest. FCOI Report This section applies to PHS-funded Research. If an Investigator has a Significant Financial Interest that is related to Research funded by another Agency, the Signing Official should consult with the general counsel to determine the applicable reporting requirements. Responsible Department: Legal Affairs Page 5 of 9

The Institute shall provide FCOI reports to the corresponding PHS Awarding Component regarding all FCOI prior to the expenditure of funds or within sixty (60) days of any subsequently identified FCOI. An FCOI report shall include sufficient information to enable the PHS Awarding Component to understand the nature and extent of the financial conflict, and to assess the appropriateness of the Institute s Management Plan. The FCOI report shall include, at a minimum, the following: Project number; PI (or a contact PI, if a multiple PI model is used); Name of the Investigator with the FCOI; Name of the entity with which the Investigator has an FCOI; Nature of the financial interest; Value of the financial interest or a statement that the interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value; A description of how the financial interest related to the PHS-funded Research and the basis for the Institute s determination that the financial interest conflicts with such Research; and A description of the key elements of the Institute s Management Plan, including: - Role and principal duties of the conflicted Investigator in the Research project; - Conditions of the Management Plan; - How the Management Plan is designed to safeguard objectivity in the Research project; - Confirmation of the Investigator s agreement to the Management Plan; - How the Management Plan will be monitored to ensure Investigator compliance; and - Other information, as needed. If the FCOI is identified and eliminated prior to the expenditure of any federally-awarded funds, no FCOI report need be submitted. For any FCOI previously reported by the Institute with regard to ongoing PHS-funded Research and for the duration of the project period, the Institute shall provide to the corresponding PHS Awarding Component an annual FCOI report that addresses the status of the FCOI and any changes to the Management Plan for the duration of the PHS-funded Research. This annual FCOI report shall specify whether the FCOI is still being Managed or explain why the FCOI no longer exists. Noncompliance and Remedies Whenever the Institute identifies a Significant Financial Interest that was not disclosed timely by an Investigator or was not previously reviewed by the Institute during an ongoing Agency-funded Research project, the Signing Official shall, within sixty (60) days, review the Significant Financial Interest, determine whether it is related to Agency-funded Research, and determine whether an FCOI exists. If an FCOI exists, the Signing Official shall implement, on at least an interim basis, a Management Plan that shall specify the actions that have been, and will be taken, to Manage such FCOI going forward. If an Investigator has failed to comply with a Management Plan, or for whatever reason, an FCOI is one Responsible Department: Legal Affairs Page 6 of 9

that was not identified, reviewed or Managed in a timely manner, the Signing Official shall, within onehundred twenty (120) days of the Institute s determination of noncompliance, conduct a retrospective review of the Investigator s activities and the Research project to determine whether any Agency-funded Research or portion thereof conducted during the period of noncompliance was biased in design, conduct or reporting. The review shall be documented; such documentation shall include the following: Project number; Project title; PI (or contact PD, if a multiple PD model is used); Name of the Investigator with the FCOI; Name of the entity with which the Investigator as a FCOI; Reasons for the retrospective review; Detailed methodology used for the retrospective review; Findings of the review; and Conclusions of the review. If bias is found during the course of the review, the Signing Official will promptly notify the corresponding Agency Awarding Component (which may take its own action and/or require further action by the Institute and/or the Investigator, as it deems appropriate), and for PHS and for any other Agency that requires such a response, submit a mitigation report. The mitigation report must include the key elements documented in the retrospective review above and a description of the impact of the bias on the Research project and the Institute s plan of action or actions taken to eliminate or mitigate the effect of the bias (e.g., impact on the Research project; extent of harm done, including any data to support any actual or future harm; analysis of whether the Research project is salvageable). If appropriate, the Signing Official will update the previously submitted FCOI report, specifying the actions that will be taken to Manage the FCOI going forward. In any event, the Signing Official shall submit FCOI reports annually thereafter. The Signing Official will notify the corresponding Agency Awarding Component and any other relevant authority in the Agency immediately if an Investigator fails to comply with the FCOI Policy or if a Management Plan appears to have biased the design, conduct, or reporting of the Agency-funded Research. The Signing Official will then develop and implement corrective action to address such noncompliance or Management Plan. Maintenance of Records The Signing Official shall maintain all records relating to all Investigator disclosures of financial interest and the Institute s review of, and response to, such disclosures and all actions under this Policy for a period of three (3) years from the date of submission of the final expenditures report to the funding Agency (or, where applicable, from other dates specified in 45 CFR 75.361). For NSF-funded Research, the Signing Official must maintain records of all financial disclosures and of all actions taken to resolve conflicts of interest for at least three (3) years beyond the termination or completion of the grant to which they relate, or until the resolution of any NSF action involving those records, whichever is longer. Responsible Department: Legal Affairs Page 7 of 9

Subrecipient Requirements If the Institute carries out Agency-funded Research through a subrecipient, the Institute must take reasonable steps to ensure that subrecipient Investigators comply with the FCOI Regulations or other applicable Agency rules. In furtherance of this requirement, the Institute must incorporate into any written agreement with a subrecipient, terms that establish whether this Policy or the subrecipient s FCOI policy will apply to the subrecipient s Investigators. The subrecipient s FCOI policy may apply if the subrecipient certifies as part of the agreement that its FCOI policy complies with the FCOI Regulations or other applicable Agency rules. Otherwise, this Policy shall apply to the subrecipient s Investigators. If the subrecipient s FCOI policy applies, then the agreement shall specify time periods for the subrecipient to report all identified FCOI to the Institute; such time periods shall be sufficient to enable the Institute to comply timely with any reporting obligations. Alternatively, if this Policy applies, the agreement shall specify time periods for the subrecipient to submit all Investigator disclosure of Significant Financial Interests to the Institute; such time periods shall be sufficient to enable the Institute to comply timely with its review, Management, and reporting obligations. The Institute shall also provide FCOI reports to the corresponding Agency Awarding Component regarding all FCOI of all subrecipient Investigators prior to the expenditure of funds or within sixty (60) days of any subsequently identified FCOI. Public Accessibility Requirements Prior to expending any funds under an Agency-funded Research project, the Institute shall ensure public accessibility to information concerning an active and disclosed FCOI related to Agency-funded Research providing a written response to any written request, such response to be postmarked or dated (if replying by electronic means) within five (5) business days of the receipt of the written request. Such information shall include the following: The Investigator s (or Senior/Key Personnel) name; The Investigator s (or Senior/Key Personnel) title and role with respect to the Research project; The name of the entity in which the Significant Financial Interest is held; The nature of the Significant Financial Interest; and The approximate dollar value of the Significant Financial Interest, or a statement that the interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value. The Institute will note in its written response that the information provided is current as of the date of the correspondence and is subject to updates, on at least an annual basis and within sixty (60) days of the Institute s identification of a new FCOI, which should be requested subsequently by the requestor. This Policy shall be posted on the Institute s website. Additional Information The Institute may be asked to provide records related to this Policy, including disclosure forms, to the Department of Health and Human Services, NSF, or other Agencies. The Institute will provide the requested information and make any other disclosures necessary to comply with this Policy or as required by law. Such records may be requested and provided whether or not the disclosure resulted in a determination that an FCOI existed. Responsible Department: Legal Affairs Page 8 of 9

Enforcement Mechanism and Sanctions All Investigators to whom this Policy applies are expected to fully and promptly comply with it. The Institute may impose sanctions for noncompliance which may include, but is not limited to, the following: Failure to make timely, full or accurate disclosures; Failure to provide information requested; Failure to update a disclosure form as necessary; or Failure to comply with a Management Plan. For Institute employees, sanctions may include suspension or termination, denial of eligibility to engage in the Research at issue, or other appropriate penalties. Such sanctions may require giving notice of relevant information to funding agencies, professional bodies or journals, or the public. For subrecipient investigators, sanctions may include suspension or expulsion from participation in the Research at issue and/or further Institute research. Responsible Department: Legal Affairs Page 9 of 9